EUVIMEDEUVIMED entdecken
Crossref

KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy

Jiacheng Guo, Ni Li, Qiuli Liu, Zongyao Hao, Guanghui Zhu, Xuege Wang, Hanling Wang, Qiang Pan, Beitao Xu, Ying Han, Guoying Zhang, Yannan Lian und 12 weitere

Cancer Cell · 2025

DOI: 10.1016/j.ccell.2025.04.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2025. Verfasst von Jiacheng Guo und 23 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Androgen, Cell Transdifferentiation, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 94 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, Shanghai Rising-Star Program, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Double-negative prostate cancer (DNPC), characterized by an androgen receptor (AR)- and neuroendocrine-null phenotype, frequently emerges following androgen deprivation therapy (ADT). However, our understanding of the origins and regulatory mechanisms of DNPC remains limited. Here, we discover that tumors with KMT2C mutation or loss are highly susceptible to transitioning into DNPC following ADT. We clarify that DNPC primarily stems from luminal cell transdifferentiation rather than basal cell transformation. Antiandrogen treatment induces KMT2C binding at enhancers of a subset of AR-regulated genes, preserving the adenocarcinoma lineage. KMT2C maintains ASPP2 expression via enhancer-promoter communication post-AR inhibition, while its inactivation reduces ASPP2, triggering ΔNp63-dependent transdifferentiation. This DNPC transition maintains fatty acid (FA) synthesis through ΔNp63-mediated SREBP1c transactivation, fueling DNPC growth via HRAS palmitoylation and MAPK signaling activation. These findings highlight KMT2C as an epigenetic checkpoint against DNPC development and suggest the therapeutic potential of targeting fatty acid synthesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsReceptors, AndrogenCell TransdifferentiationDrug Resistance, NeoplasmDNA-Binding ProteinsNeoplasm ProteinsMaleHumansAnimalsMiceCell Line, TumorAndrogen AntagonistsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

double-negative prostate cancerepigenetic barrierlineage plasticitytansdifferentiation

Substanzen

Receptors, AndrogenKMT2C protein, humanAndrogen AntagonistsAR protein, humanDNA-Binding ProteinsNeoplasm Proteins

Autor:innen und Institutionen

  • Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
  • Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; Jinfeng Laboratory, Chongqing 401329, China. Electronic addre…
  • Department of Urology, Daping Hospital, Army Medical University, Chongqing 400042, China.
  • Department of Urology, the First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei 230022, China.
  • West China School of Public Health, West China Fourth Hospital, and State Key Laboratory of Biotherapy, Sichuan University, Chengdu 610000, China.
  • Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; Jinfeng Laboratory, Chongqing 401329, China.

Förderung

  • Key Technologies Research and Development Program
  • Shanghai Rising-Star Program
  • National Natural Science Foundation of China
  • National Natural Science Foundation of China National Outstanding Youth Science Fund Project
  • National Key Research and Development Program of China
  • Youth Innovation Promotion Association of the Chinese Academy of Sciences
  • Chinese Academy of Sciences

Zitieren

APA

Guo, J., Li, N., Liu, Q., Hao, Z., Zhu, G., Wang, X., Wang, H., Pan, Q., Xu, B., Han, Y., Zhang, G., Lian, Y., Zhang, W., Gu, Y., Lin, N., Zeng, X., Jin, Z., Lan, W., Jiang, J., …, & Qin, J. (2025). KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy. Cancer Cell. https://doi.org/10.1016/j.ccell.2025.04.002

Vancouver

Guo J, Li N, Liu Q, Hao Z, Zhu G, Wang X, et al. KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy. Cancer Cell. 2025. doi:10.1016/j.ccell.2025.04.002

BibTeX
@article{Guo2025,
  author = {Guo, Jiacheng and Li, Ni and Liu, Qiuli and Hao, Zongyao and Zhu, Guanghui and Wang, Xuege and Wang, Hanling and Pan, Qiang and Xu, Beitao and Han, Ying and Zhang, Guoying and Lian, Yannan and Zhang, Wei and Gu, Yongqiang and Lin, Naiheng and Zeng, Xin and Jin, Zige and Lan, Weihua and Jiang, Jun and Gao, Dong and Dong, Liang and Yuan, Huairui and Liang, Chaozhao and Qin, Jun},
  title = {KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy},
  journal = {Cancer Cell},
  year = {2025},
  doi = {10.1016/j.ccell.2025.04.002}
}
Kostenlos starten →